Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
Q1 2026 earnings • released • EPS beat +11,14% • Revenue beat +5,24%
See results
BMY:NYSE
Bristol-Myers Squibb Co
58,22 US$
-3,91%
(-2,37) 1D
58,50 US$
+0,48% (+0,28)
After hours
Closed: 1 მაი, 16:00:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMY...
Open
60,02 US$
High
60,08 US$
Low
58,03 US$
Mkt. cap
118,87 მლრ.
Volume
18,37 მლნ.
Dividend
4,33%
Quarterly dividend
0,63 US$
Ex dividend date
2 იან. 2026
P/E ratio
16,34
52-wk high
62,89 US$
52-wk low
42,52 US$
EPS
3,56 US$
Beta
0,27
Shares outstanding
2,04 მლრდ.
No. of employees
32 ათ.
News stories
From sources across the web
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOქრის ბერნერი
Employees32,5 ათ.
Founded1887
Headquartersნიუ-იორკი, ნიუ-იორკის შტატი, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Websitebms.com
Last report
30 აპრ. 2026
Fiscal Period
Q1 2026
Normalized EPS / Estimate
1,58/ (1,42 est.)USD
+11,14%beat
Revenue / Estimate
11,49 მლრდ./ (10,92 მლრდ. est.)USD
+5,24%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
მარ. 2025
ივნ. 2025
სექ. 2025
დეკ. 2025
Revenue
11,20 მლრდ.
12,27 მლრდ.
12,22 მლრდ.
12,50 მლრდ.
Cost of goods sold
3,02 მლრდ.
3,36 მლრდ.
3,31 მლრდ.
3,51 მლრდ.
Cost of revenue
3,02 მლრდ.
3,36 მლრდ.
3,31 მლრდ.
3,51 მლრდ.
Research and development expenses
2,24 მლრდ.
2,26 მლრდ.
2,43 მლრდ.
2,56 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,58 მლრდ.
1,69 მლრდ.
1,79 მლრდ.
2,09 მლრდ.
Operating expense
4,65 მლრდ.
4,78 მლრდ.
5,05 მლრდ.
5,47 მლრდ.
Total operating expenses
7,66 მლრდ.
8,14 მლრდ.
8,36 მლრდ.
8,98 მლრდ.
Operating income
3,54 მლრდ.
4,13 მლრდ.
3,86 მლრდ.
3,52 მლრდ.
Other non operating income
494,00 მლნ.
399,00 მლნ.
529,00 მლნ.
544,00 მლნ.
EBT including unusual items
2,97 მლრდ.
1,77 მლრდ.
3,11 მლრდ.
1,47 მლრდ.
EBT excluding unusual items
3,70 მლრდ.
4,22 მლრდ.
4,07 მლრდ.
3,86 მლრდ.
Income tax expense
509,00 მლნ.
460,00 მლნ.
919,00 მლნ.
384,00 მლნ.
Effective tax rate
17,13%
25,96%
29,51%
26,12%
Other operating expenses
-
-
-
-
Net income
2,46 მლრდ.
1,31 მლრდ.
2,20 მლრდ.
1,09 მლრდ.
Net profit margin
21,93%
10,68%
18,01%
8,69%
Earnings per share
1,80
1,46
1,63
1,26
Interest and investment income
138,00 მლნ.
139,00 მლნ.
161,00 მლნ.
148,00 მლნ.
Interest expense
-493,00 მლნ.
-485,00 მლნ.
-482,00 მლნ.
-432,00 მლნ.
Net interest expenses
-355,00 მლნ.
-346,00 მლნ.
-321,00 მლნ.
-284,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
4,55 მლრდ.
5,12 მლრდ.
4,91 მლრდ.
4,54 მლრდ.
Gain or loss from assets sale
-20,00 მლნ.
-7,00 მლნ.
-9,00 მლნ.
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer